Media coverage
9
Media coverage
Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet PharmiWeb Country/Territory United Kingdom Date 20/6/17 URL https://www.pharmiweb.com/press-release/2020-06-17/new-phase-ii-data-indicate-regimen-of-truxima-biosimilar-rituximab-lenalidomide-and-acalabrutinib-r2a-may-be-well-tolerated-and-effective-in-rel-1 Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet MarketScreener.com Country/Territory United States Date 20/6/15 URL https://www.marketscreener.com/news/New-Phase-II-data-indicate-regimen-of-Truxima-biosimilar-rituximab-lenalidomide-and-acalabrutini--30769679/ Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet Market Newsdesk Country/Territory United States Date 20/6/15 URL www.marketnewsdesk.com/?p=285808 Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet Jotup Country/Territory United States Date 20/6/15 URL https://jotup.co/node/819280 Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet Crwe World Country/Territory United States Date 20/6/15 URL crweworld.com/article/news-provided-by-business-wire/1571544/new-phase-ii-data-indicate-regimen-of-truxima-biosimilar-rituximab-lenalidomide-and-acalabrutinib-r2a-may-be-well-tolerated-and-effective-in-relapsedrefractory-aggressive-b-cell-lymphoma Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet Business Wire Country/Territory United States Date 20/6/15 URL https://www.businesswire.com/news/home/20200614005011/en/New-Phase-II-data-regimen-Truxima%C2%AE-biosimilar Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet Digital Media Net Country/Territory United States Date 20/6/15 URL dmnnewswire.digitalmedianet.com/2020/06/15/new-phase-ii-data-indicate-regimen-of-truxima-biosimilar-rituximab-lenalidomide-and-acalabrutinib-r2a-may-be-well-tolerated-and-effective-in-relapsed-refractory-aggressive-b-cell-lymphoma/?utm_source=rss&utm_medium=rss&utm_campaign=new-phase-ii-data-indicate-regimen-of-truxima-biosimilar-rituximab-lenalidomide-and-acalabrutinib-r2a-may-be-well-tolerated-and-effective-in-relapsed-refractory-aggressive-b-cell-lymphoma Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet Global Banking & Finance Review Country/Territory United Kingdom Date 20/6/14 URL https://www.globalbankingandfinance.com/category/news/new-phase-ii-data-indicate-regimen-of-truxima-biosimilar-rituximab-lenalidomide-and-acalabrutinib-r2a-may-be-well-tolerated-and-effective-in-relapsed-refractory-aggressive-b-cell-lymphoma/ Persons Ki woo Kim Title New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Media name/outlet Business Wire Country/Territory United States Date 20/6/14 Persons Ki woo Kim